These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 23293836)

  • 1. Cathepsin B as a cancer target.
    Gondi CS; Rao JS
    Expert Opin Ther Targets; 2013 Mar; 17(3):281-91. PubMed ID: 23293836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin B and L inhibitors: a patent review (2010 - present).
    Li YY; Fang J; Ao GZ
    Expert Opin Ther Pat; 2017 Jun; 27(6):643-656. PubMed ID: 27998201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular regulation of human cathepsin B: implication in pathologies.
    Yan S; Sloane BF
    Biol Chem; 2003 Jun; 384(6):845-54. PubMed ID: 12887051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells.
    Liu F; Li X; Lu C; Bai A; Bielawski J; Bielawska A; Marshall B; Schoenlein PV; Lebedyeva IO; Liu K
    Oncotarget; 2016 Dec; 7(51):83907-83925. PubMed ID: 27880732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Cathepsin B in Cancer Progression: A Potential Target for Coordination Compounds.
    Akinyemi AO; Pereira GBS; Rocha FV
    Mini Rev Med Chem; 2021; 21(13):1612-1624. PubMed ID: 33583372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
    Yin M; Soikkeli J; Jahkola T; Virolainen S; Saksela O; Hölttä E
    Am J Pathol; 2012 Dec; 181(6):2202-16. PubMed ID: 23063511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cathepsin B and human tumor progression.
    Yan S; Sameni M; Sloane BF
    Biol Chem; 1998 Feb; 379(2):113-23. PubMed ID: 9524062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression.
    Iacobuzio-Donahue CA; Shuja S; Cai J; Peng P; Murnane MJ
    J Biol Chem; 1997 Nov; 272(46):29190-9. PubMed ID: 9360997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of cathepsin B and uPAR inhibits CD151 and α3β1 integrin-mediated cell adhesion and invasion in glioma.
    Rao Malla R; Gopinath S; Alapati K; Gorantla B; Gondi CS; Rao JS
    Mol Carcinog; 2013 Oct; 52(10):777-90. PubMed ID: 22495828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin inhibition-induced lysosomal dysfunction enhances pancreatic beta-cell apoptosis in high glucose.
    Jung M; Lee J; Seo HY; Lim JS; Kim EK
    PLoS One; 2015; 10(1):e0116972. PubMed ID: 25625842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of uPAR and cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhibition of the PI3K/Akt pathway in gliomas.
    Malla R; Gopinath S; Alapati K; Gondi CS; Gujrati M; Dinh DH; Mohanam S; Rao JS
    PLoS One; 2010 Oct; 5(10):e13731. PubMed ID: 21060833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin B promotes colorectal tumorigenesis, cell invasion, and metastasis.
    Bian B; Mongrain S; Cagnol S; Langlois MJ; Boulanger J; Bernatchez G; Carrier JC; Boudreau F; Rivard N
    Mol Carcinog; 2016 May; 55(5):671-87. PubMed ID: 25808857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current stage of cathepsin B inhibitors as potential anticancer agents.
    Kos J; Mitrović A; Mirković B
    Future Med Chem; 2014 Jul; 6(11):1355-71. PubMed ID: 25163003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Cathepsin B for Cancer Therapies.
    Ruan H; Hao S; Young P; Zhang H
    Horiz Cancer Res; 2015 2nd Quarter; 56():23-40. PubMed ID: 26623174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-chaperone BAG2 Determines the Pro-oncogenic Role of Cathepsin B in Triple-Negative Breast Cancer Cells.
    Yang KM; Bae E; Ahn SG; Pang K; Park Y; Park J; Lee J; Ooshima A; Park B; Kim J; Jung Y; Takahashi S; Jeong J; Park SH; Kim SJ
    Cell Rep; 2017 Dec; 21(10):2952-2964. PubMed ID: 29212038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cathepsin B levels, urinary excretion of cathepsin B and tissue cathepsin B content in the patients with gastric cancer.
    Hirano T; Yoshioka H
    Nihon Geka Hokan; 1993 Sep; 62(5):217-21. PubMed ID: 8031215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescent microplate assay for cancer cell-associated cathepsin B.
    Hulkower KI; Butler CC; Linebaugh BE; Klaus JL; Keppler D; Giranda VL; Sloane BF
    Eur J Biochem; 2000 Jul; 267(13):4165-70. PubMed ID: 10866820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.
    Kubisch R; Fröhlich T; Arnold GJ; Schreiner L; von Schwarzenberg K; Roidl A; Vollmar AM; Wagner E
    Int J Cancer; 2014 May; 134(10):2478-88. PubMed ID: 24166050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.
    Luan H; Mohapatra B; Bielecki TA; Mushtaq I; Mirza S; Jennings TA; Clubb RJ; An W; Ahmed D; El-Ansari R; Storck MD; Mishra NK; Guda C; Sheinin YM; Meza JL; Raja S; Rakha EA; Band V; Band H
    Cancer Res; 2018 May; 78(10):2524-2535. PubMed ID: 29510992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cathepsin B inhibitors: Further exploration of the nitroxoline core.
    Sosič I; Mitrović A; Ćurić H; Knez D; Brodnik Žugelj H; Štefane B; Kos J; Gobec S
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1239-1247. PubMed ID: 29503024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.